nav.hidden, nav ul [x-cloak], nav ul li ul { display: block !important; } This website requires Javascript for some parts to function properly. Your experience may vary.

This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Essential Essential cookies enable basic functions and are necessary for the website to function properly. Marketing Marketing cookies are used by third parties or publishers to display personalized advertisements. They do this by tracking visitors across websites.

Log out

Change Cookie Settings

Forgot Password? Click here

Cookie consent is required to register and log in

I am a Healthcare professional outside US

Subscribe me to the regular newsletter

Notice: The content of this website is not intended for U.S. residents.

This website has implemented reCAPTCHA v3 and your use of reCAPTCHA v3 is subject to the Google Privacy Policy and Terms of Use.

Log out

Change Cookie Settings

Forgot Password? Click here

Cookie consent is required to register and log in

I am a Healthcare professional outside US

Subscribe me to the regular newsletter

Notice: The content of this website is not intended for U.S. residents.

This website has implemented reCAPTCHA v3 and your use of reCAPTCHA v3 is subject to the Google Privacy Policy and Terms of Use.

Clinical Studies

ITM's Clinical Trials for GEP-NET Patients

Two phase 3 clinical trials are undergoing to evaluate targeted radionuclide therapy with n.c.a. lutetium-177-edotreotide in patients with neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NETs).

COMPETE - Treatment Schedule

COMPOSE - Treatment Schedule

For more information, please check out www.itm-gep-net-trials.com